Fintech PR
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
DUBLIN, Sept. 3, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the “Issuer”), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Issuer also expects to grant the initial purchasers of the notes an option, exercisable within a period of 13 days from and including the date the notes are first issued, to purchase up to an additional $150 million aggregate principal amount of notes.
The notes will be exchangeable under certain conditions. The Issuer will settle exchanges by paying cash up to the aggregate principal amount of the notes to be exchanged. The remainder, if any, of the Issuer’s exchange obligation in excess of the aggregate principal amount of the notes, will be settled in cash, ordinary shares of Jazz Pharmaceuticals (“ordinary shares”) or a combination of cash and ordinary shares, at the Issuer’s election. The interest rate, initial exchange rate and other terms of the notes will be determined at the time of pricing of the offering.
The notes will be general unsecured obligations of the Issuer and will accrue interest payable semiannually in arrears. The Issuer’s obligations under the notes will be fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals; will rank pari passu in right of payment with the Issuer’s existing 2.000% exchangeable senior notes due 2026; will be effectively subordinated to the Issuer’s guarantees of the indebtedness under Jazz Pharmaceuticals’ credit agreement (the “credit agreement”) and Jazz Pharmaceuticals’ 4.375% senior secured notes due 2029 (the “senior secured notes”) to the extent of the value of the assets securing such guarantees; and will be structurally subordinated to the indebtedness and guarantees under the credit agreement and the senior secured notes of Jazz Pharmaceuticals’ other subsidiaries that are borrowers or have provided guarantees of such indebtedness.
Jazz Pharmaceuticals, together with its consolidated subsidiaries (“Jazz”), expects to use a portion of the net proceeds to prepay up to approximately $350 million of the term loans outstanding under the credit agreement and the remainder for general corporate purposes. If the initial purchasers exercise their option to purchase additional notes, Jazz expects to use the net proceeds from the sale of the additional notes for further prepayments of the term loans.
Jazz Pharmaceuticals also expects to repurchase up to $150 million of its ordinary shares from purchasers of the notes in privately negotiated transactions with or through one of the initial purchasers or its affiliate concurrently with the pricing of the offering (the “concurrent ordinary share repurchases”). Jazz Pharmaceuticals expects the purchase price per ordinary share repurchased in such concurrent ordinary share repurchases to equal the closing price per ordinary share on the date of the offering. To the extent Jazz Pharmaceuticals effects any such concurrent ordinary share repurchases, it will pay for such repurchases with existing cash on hand and such repurchases will be effected as part of Jazz Pharmaceuticals’ share repurchase program announced in July 2024. Accordingly, any such concurrent ordinary share repurchases will reduce the remaining amount authorized under the share repurchase program. No assurance can be given as to how much, if any, of Jazz Pharmaceuticals’ ordinary shares will be repurchased or the terms on which they will be repurchased. The concurrent ordinary share repurchases could increase, or reduce the size of any decrease in, the market price of the ordinary shares, including concurrently with the pricing of the notes, resulting in a higher effective exchange price for the notes. This press release is not an offer to repurchase the ordinary shares, and the offering of the notes is not contingent upon the repurchase of any ordinary shares.
None of the notes, the guarantee or the ordinary shares issuable upon exchange of the notes, if any, have been registered under the Securities Act or the securities laws of any other jurisdiction, and, unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the offering and the proposed terms of the notes; the expected use of the net proceeds from the offering, including any prepayment of the term loans outstanding under the credit agreement; the timing and amount of the concurrent ordinary share repurchases and the potential impacts thereof; and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals’ current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Do not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market risks, trends and conditions, and Jazz Pharmaceuticals’ ability to complete the offering and the concurrent ordinary share repurchases on the proposed terms and timing. These and other risks and uncertainties affecting Jazz Pharmaceuticals, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals’ Securities and Exchange Commission filings and reports, including Jazz Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and any future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results due to any new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Contacts:
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland, +353 1 634 3211
U.S. +1 650 496 2717
Logo – https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg
View original content:
Fintech is on an accelerated trajectory of investment, collaboration, and innovation. This pulse tracks the most significant developments in the sector, from high-profile investments to global platform expansions. Each update in this briefing serves as a key indicator of where the industry is headed.
1. European Fintechs Face Regulatory Pressures Amid New Investment Surge
The European fintech sector finds itself at a crossroads with increasing scrutiny and rising costs due to stringent regulations. While investments continue to flow into the continent’s financial technology companies, challenges in meeting new compliance requirements, especially around data privacy and cybersecurity, create a complex landscape for scaling. This tension between opportunity and operational limitations might affect European fintechs’ growth strategies.
Source: Financial Times
2. Shopify, Slack Founders Join Peter Thiel in Fintech Investment Push
Tobi Lütke of Shopify and Stewart Butterfield of Slack, along with investor Peter Thiel, have co-invested in a new fintech initiative that aims to bolster small business access to capital. By merging technology with a streamlined funding model, this new initiative targets underserved SMBs, highlighting a broader trend of high-profile tech leaders pivoting to fintech investment. The participation of Lütke and Butterfield signals increased cross-sector collaboration in fintech, bringing expertise from e-commerce and communication technology into the financial arena.
Source: Yahoo Finance
3. Lean Technologies Raises $67.5 Million to Drive Fintech Innovation in the Middle East
Riyadh-based fintech platform Lean Technologies recently secured a $67.5 million Series B investment round, aiming to expand its operations across the Middle East. This funding reflects growing investor interest in emerging markets and the potential of Middle Eastern fintech to bridge regional gaps in financial services access. As Lean Technologies broadens its service offerings, the funding will support further technological integration and scalability across financial ecosystems in the region.
Source: Fintech Global
4. Apollo Global Management Invests in Fintech for Private Offerings Support
Apollo Global Management has taken steps to enhance its services for private offerings by investing in specialized fintech solutions. This development signifies a growing trend among private equity firms to adopt fintech as a core component in their service expansion, particularly for personalized client services. Apollo’s strategy of integrating fintech solutions into private offerings marks a strategic shift toward digitalization within traditional financial sectors.
Source: Bloomberg
5. Juniper Research Names 2025’s Future Leaders in Fintech
Juniper Research has revealed its picks for the top future leaders in fintech for 2025. This list emphasizes innovation in fields such as AI, open banking, and decentralized finance, highlighting startups that exhibit potential for reshaping industry standards. As these up-and-coming firms push the boundaries of traditional finance, they exemplify the rising tide of next-generation financial technology poised to become industry mainstays.
Source: Globe Newswire
Conclusion
The convergence of seasoned tech giants with fintech, new funding rounds for region-specific platforms, and the rise of future industry leaders underscore the momentum of the fintech sector. Each of these stories reflects a broader narrative: fintech is not only diversifying in services but also rapidly integrating into traditional finance and tech, paving the way for a transformative era.
The post Fintech Pulse: Evolving Fintech Investments and Partnerships Signal Industry Transformation appeared first on HIPTHER Alerts.
Fintech PR
Notabene Raises $14.5M in Series B Funding Led by DRW VC to Drive the Future of Stablecoins and Payments
The rapid adoption of Notabene’s crypto payment authorization network, which has seen transaction volumes surge 10X in the past year, reflects the growing demand for compliant crypto payment solutions. This Series B round will help Notabene bring secure, transparent, and compliant crypto payments to more financial institutions, paving the way for stablecoins to revolutionize global finance.
NEW YORK, Nov. 12, 2024 /PRNewswire/ — Notabene, a leading provider of cryptocurrency compliance solutions, today announced it has raised $14.5 million in a Series B funding round led by DRW VC, with participation from funds managed by Apollo, NextBlock, ParaFi Capital, and Wintermute, along with existing investors CMT Digital, F-Prime, Green Visor Capital, Illuminate Financial, Jump Capital, Signature Ventures, and Y Combinator. The funding will accelerate Notabene’s mission to make crypto payments a part of the everyday global economy by fostering open, secure, and compliant transactions.
Regulators now require crypto companies such as exchanges, wallet providers, and payment processors to securely exchange information about sender and receiver, just like they already do in traditional payments. This so-called Travel Rule is now a requirement in most global financial centers.
Having already helped process half a trillion dollars worth of transactions, Notabene is the leading global platform and network for compliant crypto payments. By automating the secure transfer of sensitive data between institutions, Notabene simplifies this complex process that is virtually impossible for companies to implement independently.
Kimberly Trautmann, Partner and Head of DRW VC, the round’s lead investor, emphasized the significance of Notabene’s work in this emerging financial ecosystem:
“Notabene offers a comprehensive and efficient way to track and disclose who an asset is being sent to, which is critical for those who facilitate the exchange, transfer, safekeeping, and administration of virtual assets (Virtual Asset Service Partners or VASPs) and need to be compliant with the Travel Rule. We believe Notabene is positioned to be the provider-of-choice, as it allows users to achieve real-time compliance, is protocol agnostic and does not require exposing sensitive information to other market participants.”
Notabene is expanding its focus to support the growing number of traditional financial institutions moving into digital payments. With over $20T in stablecoin transactions processed last year, global adoption is on the rise and poised to be crypto’s long-awaited killer use case. The key to unlocking stablecoins’ potential as fast, low-cost, borderless payments is a secure and transparent system – one that’s open and not controlled by any single entity. Notabene offers the essential infrastructure for compliance, reconciliation, and safety, enabling open, interoperable payment networks that will drive the next wave of adoption.
Notabene’s CEO, Pelle Brændgaard, underscores the company’s vision for the future of payments:
“We’ve already established ourselves as a pioneer in Travel Rule compliance, and now, as regulatory clarity grows and adoption scales, we are positioned to do the same for payments. By enabling secure, compliant, and open digital asset transactions, we’re helping shape the next generation of global financial infrastructure. Our philosophy of building open networks to maximize reachability between transacting counterparties will be a key driver of adoption with both crypto-native organizations, as well as incumbent players in traditional finance that are showing an increased interest in digital assets and blockchain payment solutions.”
Notabene’s platform has seen a rapid 10x increase in transaction volumes over the past year, totaling nearly $500 billion in transaction volume—solidifying the company’s role as a trusted provider in the compliance space. With over 165 companies using the platform, including some of the largest virtual asset service providers (VASPs) globally such as Copper, Crypto.com, OKX, and Ramp, as well as working relationships with regulatory bodies across hundreds of global jurisdictions, Notabene has built the largest network of transacting counterparties in the market today.
Alexander Ross, General Partner, Head of NYC for investor Illuminate Financial, added:
“As the existing market leader for Travel Rule compliance, we believe Notabene has the potential to become the “SWIFT network for blockchain transactions.” There is a desperate need for a secure network to share all transaction metadata. This will enable compliance with global regulations and is a key pillar to unlocking mass adoption of stablecoins for payments. We have been working with the founders since 2021 and believe they are the best positioned to execute this vision.”
With this raise, Notabene is set to continue its mission to bring crypto and stablecoins into everyday global payments. It will help grow the industry’s only open compliant payments network to support more use cases and new market entrants.
“With $20 trillion in stablecoin transactions processed last year, stablecoins are emerging as the preferred method for fast, low-cost global payments,” said Pelle Brændgaard, Notabene CEO. “As regulatory clarity expands, traditional financial institutions are beginning to recognize stablecoins’ potential. Notabene’s role as a trusted compliance provider is critical to unlocking this potential and establishing stablecoins as a legitimate payment medium worldwide.”
About Notabene
Notabene is the leading crypto payment authorization network, enabling secure, transparent, and compliant transactions for financial institutions around the world. With a platform that facilitates transactions in over 80 jurisdictions, supports over 165 companies, and has processed half a trillion dollars in transaction volume, Notabene is setting the standard for compliant transactions in the digital asset space.
For more information, please visit Notabene.id.
Photo – https://mma.prnewswire.com/media/2555310/Notabene_Series_B_Fundraise_Announcement.jpg
Logo – https://mma.prnewswire.com/media/2555309/Notabene_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/notabene-raises-14-5m-in-series-b-funding-led-by-drw-vc-to-drive-the-future-of-stablecoins-and-payments-302303062.html
TALLINN, Estonia, Nov. 12, 2024 /PRNewswire/ — Bluestream OÜ, a quickly expanding digital finance company, is proud to announce the launch of three loan comparison websites aimed at simplifying the loan search process for Finnish consumers. The recently introduced platforms – “Laina heti”, “Luotto”, and “Lainojen yhdistäminen” – are designed to provide transparent, easy-to-understand and reliable financing comparison services designed to meet the diverse financial needs of consumers across Finland.
Laina heti: Speed and Simplicity for Urgent Loans
One of the three platforms, Laina Heti focuses on helping users find fast and convenient loans. This website caters to individuals who require quick access to funds for emergency expenses, unexpected bills or time-sensitive purchases. The design of the website emphasizes simplicity and efficiency, providing users with comparisons of short-term loan offers, including payday loans and other fast financial products.
Luotto: Comprehensive Loan Solutions for All Borrowers
The second platform, Luotto, is the company’s comprehensive comparison website for personal loans. Unlike Laina heti, which focuses on immediate and short-term needs, Luotto is designed to serve consumers seeking more substantial loans for a wider range of financial purposes. Whether it’s for a new car or home renovations, the website provides users with a detailed comparison of various loan options offered by banks, credit institutions, and other lenders across Finland.
Lainojen yhdistäminen: Simplifying Debt Consolidation for Finnish Consumers
The third and final platform, Lainojen yhdistäminen specifically targets consumers looking to consolidate several loans into a single, more manageable monthly payment. For many individuals facing the challenge of managing several loans at once – such as personal loans, credit card debt, or payday loans – loan consolidation can be an effective way to reduce financial stress, improve budgeting and potentially lower the total cost of borrowing.
“With Laina Heti, Luotto and Lainojen Yhdistäminen, we wanted to make it easier for consumers to access quick loans, personal loans and debt consolidation loans without getting bogged down in complex procedures. It’s all about making sure people have the information they need at their fingertips when they need it most,” said a representative for Bluestream OÜ.
About Bluestream OÜ
Bluestream OÜ is a digital finance company based in Tallinn, Estonia. The company specializes in creating financial comparison tools that provide consumers with transparent and comprehensive information to help them make informed financial decisions.
Press Contact:
Bluestream OÜ
Email: [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/bluestream-ou-launches-three-comprehensive-loan-comparison-websites-302302960.html
-
Fintech5 days agoFintech Pulse: The Latest Trends and Insights Shaping Fintech
-
Fintech PR4 days agoConverge Technology Solutions Named Solution Partner of the Year at the 2024 Ingram Micro ONE Innovation Summit
-
Fintech PR7 days agoHTX Ventures: Fueling Exchanges’ Transformation into Hubs for DeFi-related Services through Education and Diversification, Empowering investors to Manage Risks and Liquidity in a Volatile Market
-
Fintech PR4 days agoManulife Investment Management aligns capabilities across regions under the newly created role of Global Emerging Market Equities CIO
-
Fintech PR6 days agoSmartkem to Present at the 6th National Conference on Organic Field-Effect Transistors in Hangzhou, China
-
Fintech PR4 days agoBybit and Block Scholes Uncover Post-Election Bullish Sentiment: Traders Lean Into Leveraged Longs Amid Stabilized Market
-
Fintech PR4 days agoPalm Jebel Ali Project Surges Ahead in 2024: Milestones Achieved in Record Time for Dubai’s Most Anticipated Development
-
Fintech1 day agoFintech Pulse: Industry Innovations and Partnerships Drive Global Fintech Forward